If Trump actually fires Powell, expect chaos. That’s the blunt warning from Wall Street analysts, legal professionals, and ...

Former deputy Treasury Secretary Roger Altman said he did not think Jerome Powell would agree to leave if the president asked ...

Stocks rebounded on Wednesday after President Donald Trump denied reports that he was close to ousting Powell as chairman of ...

Wolfe Research reaffirmed its ‘Outperform’ rating on UnitedHealth Group but cut its price target to $330 from $363, citing ongoing medical billing pressures. The firm highlighted that UnitedHealth’s ...

Fintel reports that on July 14, 2025, Wolfe Research downgraded their outlook for HF Sinclair (NYSE:DINO) from Peer Perform ...

Centene Corporation (NYSE:CNC) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 2, Wolfe ...

Shares of MongoDB (MDB) rose about 2% on Wednesday after Wolfe Research began coverage on the database software company with ...

Fintel reports that on July 9, 2025, Wolfe Research upgraded their outlook for Fox (NasdaqGS:FOXA) from Underperform to Peer ...

Overall, Wolfe favors a mix of growth and value as the second half of 2025 begins. Related articles Wolfe Research refreshes high-conviction ideas heading into H2 ...

Wolfe Research’s analysts highlighted that the company could see $1.8 billion in tax savings in 2025 alone. This is a 30% free cash flow (FCF) boost, potentially doubling FCF per share by 2027.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $49 price ...